Summary of use during lactation
No information is available on the clinical use of nedosiran sodium during breastfeeding. Because nedosiran is more than 85.6% bound to plasma proteins and has a molecular weight of 22,238 Da, the amount in milk is likely to be low. In addition, because nedosiran is poorly absorbed orally, it is not likely to reach the bloodstream of the infant or cause any adverse effects in breastfed infants. The drug is approved for use in children as young as 2 years old. If the mother requires nedosiran sodium, it is not a reason to discontinue breastfeeding.
Drug levels in milk and infant serum
Maternal Levels. Relevant published information was not found as of the revision date. Infant Levels. Relevant published information was not found as of the revision date.
Effects in breastfed infants
Relevant published information was not found as of the revision date.
Effects on lactation and breastmilk
Relevant published information was not found as of the revision date.
Source: Drugs and Lactation Database (LactMed®), National Institute of Child Health and Human Development, NCBI Bookshelf. Check LactMed for the most recent revision.
Medical disclaimer: This page is for qualified healthcare professionals and is a decision-support aid only. It does not replace clinical judgement, local protocols or product information. Verify every dose and threshold before use. See the full Medical Disclaimer.